Co-Diagnostics, Inc. (NASDAQ: CODX) announced that its Indian joint venture, CoSara Diagnostics Pvt. Ltd., has signed an agreement to expand its commercial and distribution territory across South Asia to include Bangladesh, Pakistan, Nepal and Sri Lanka. This expansion significantly increases CoSara's addressable market to an estimated $13.0 billion, according to the company's press release.
The expansion supports the planned commercialization of the CoSara PCR Pro(R) point-of-care platform and the SARAGENE(R) product line, subject to regulatory approvals. As the company builds regional distribution channels, it positions itself for broader deployment of its molecular diagnostics solutions across the newly added territories.
Co-Diagnostics, a Utah corporation, is a molecular diagnostics company that develops, manufactures and markets state-of-the-art diagnostics technologies. The company's technologies are utilized for tests designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The company also uses its proprietary technology to design specific tests for its Co-Dx PCR at-home and point-of-care platform (subject to regulatory review and not currently for sale) and to identify genetic markers for use in applications other than infectious disease.
The expansion into Bangladesh, Pakistan, Nepal and Sri Lanka represents a strategic move to tap into growing healthcare markets in South Asia. These countries have large populations and increasing demand for advanced diagnostic solutions. By extending its distribution network, CoSara aims to leverage existing infrastructure and partnerships to accelerate market penetration.
For more information about Co-Diagnostics and its technologies, visit https://co-dx.com/. The full press release can be accessed at https://ibn.fm/2aATV.
The announcement highlights the company's commitment to expanding its global footprint and addressing unmet diagnostic needs in emerging markets. As regulatory approvals progress, the successful commercialization of the CoSara PCR Pro platform and SARAGENE product line could provide significant growth opportunities for Co-Diagnostics and its joint venture.
